Page 149 - NobleCon20-Book-Project

Silexion Therapeutics Corp

SELECTED FINANCIAL ITEMS SLXN

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT NA NA (0.81) (1.25) N/A
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders NA NA (0.74) (1.42) N/A
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets NA NA NA 3.59 3.59
Cash & Short Term Investments NA NA NA 2.78 2.78
% of Assets NM NM NM 78% 78%
Current Assets -Total NA NA NA 3.34 3.34
% of Assets NM NM NM 93% 93%
Total Liabilities NA NA NA 1.98 1.98
% of Assets NM NM NM 55% 55%
Current Liabilities - Total NA NA NA 1.94 1.94
% of Assets NM NM NM 54% 54%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity NA NA NA 1.61 1.61
% of Assets NM NM NM 45% 45%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities NA NA (0.91) (1.75) (2.66)
Net Cash Flow - Investing NA NA 0.51 (0.01) 0.50
Net Cash Flow - Financing NA NA NA NA 0.00

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference